Intellia Therapeutics

Intellia Therapeutics is a genome editing company focused on the development of proprietary, curative therapeutics utilizing a biological tool known as the CRISPR/Cas9. The company uses the CRISPR/Cas9 system across in vivo and ex vivo applications. The company's in vivo pipeline includes proprietary programs targeting genetic diseases including transthyretin amyloidosis. The company's ex vivo pipeline consists of: a set of proprietary programs within its internal eXtellia division focused on developing engineered cell therapies; and partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells, the stem cells from which all of the various types of blood cells originate.
  • TickerNTLA
  • ISINUS45826J1051
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for NTLA

ValuEngine Rating and Forecast Report for NTLA

ValuEngine Rating and Forecast Report for NTLA

ValuEngine Rating and Forecast Report for NTLA

David Nierengarten ...
  • Jeffrey La Rosa

UPGRADING to OP; ATTR IND in 2020; Cell Therapy Program at the Heels

1 director bought

A director at Intellia Therapeutics Inc bought 7,500 shares at 15.717USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The na...

ValuEngine Rating and Forecast Report for NTLA

ValuEngine Rating and Forecast Report for NTLA

ValuEngine Rating and Forecast Report for NTLA

ValuEngine Rating and Forecast Report for NTLA

ValuEngine Rating and Forecast Report for NTLA

ValuEngine Rating and Forecast Report for NTLA

ValuEngine Rating and Forecast Report for NTLA

ValuEngine Rating and Forecast Report for NTLA

ValuEngine Rating and Forecast Report for NTLA

ValuEngine Rating and Forecast Report for NTLA

Dave Nicoski ...
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch